Gilotrif (Afatinib) 40mg Tablets | Boehringer Ingelheim Originator | GLT

Generic Information: Gilotrif (Afatinib) — International Originator

This is the international originator formulation of afatinib from Boehringer Ingelheim GmbH (Germany), the company that discovered and developed the molecule. Depending on the market, the same tablet is sold under different brand names — Gilotrif in the United States, Giotrif in Europe, and Xovoltib in India — but the active ingredient and the manufacturing quality are identical. This listing carries both the 30-tablet and 28-tablet pack sizes of the 40 mg strength, reflecting the two most common global packaging standards, and is suitable for patients and institutions seeking the reference brand outside China.

What Is Gilotrif (Afatinib)?

Gilotrif is a targeted oral therapy for non-small cell lung cancer driven by EGFR mutations. It was the first second-generation, irreversible EGFR inhibitor to reach global markets, gaining its initial approval in the United States in 2013 and subsequently in Europe, Japan, and other regions. The drug addresses a critical need: durable, first-line control of EGFR-mutant NSCLC, including uncommon mutations that first-generation agents handle poorly.

How Does Gilotrif (Afatinib) Work?

Afatinib belongs to the pan-ErbB family of kinase inhibitors. Its reactive acrylamide group forms a covalent, irreversible bond with cysteine residues in the kinase domain of EGFR, HER2 and ErbB4, permanently locking these receptors into an inactive state. This shuts down the downstream MAPK and AKT signaling cascades that cancer cells rely on for proliferation and survival, delivering a more sustained blockade than reversible inhibitors.

Indications

The international Gilotrif label covers first-line treatment of metastatic non-small cell lung cancer with non-resistant EGFR mutations, as well as metastatic squamous NSCLC that has progressed after platinum-based chemotherapy. In some regions it is also used for advanced head and neck cancers after platinum failure, reflecting its broad ErbB activity.

Dosage

The standard dose is 40 mg once daily, taken on an empty stomach — at least one hour before or two hours after food. The 30-tablet pack is the common monthly quantity in North America, while the 28-tablet pack is standard in Europe; both represent roughly a one-month course at 40 mg daily. Dose reductions to 30 mg or 20 mg may be applied to manage tolerability without sacrificing efficacy.

Side Effects

As an irreversible ErbB inhibitor, afatinib is associated with a characteristic side-effect profile: diarrhea, acneiform rash, stomatitis, paronychia, dry skin, and decreased appetite are the most frequent. Rare but serious reactions include interstitial lung disease, hepatotoxicity, keratitis, and severe bullous skin eruptions. Proactive management of diarrhea and skin toxicity is essential to keep patients on therapy.

Storage

Keep the tablets in their original container at room temperature, protected from light and moisture. The 40 mg film-coated tablets should be swallowed whole and never crushed, chewed, or split.

Why Choose the GLT?

Sourcing the international originator through GLT gives you the assurance of the reference Boehringer Ingelheim product with a transparent, reliable supply channel. We handle genuine, properly stored stock and provide the documentation that institutions and patients need for cross-border procurement. Whether you need the 30-tablet or 28-tablet pack, we confirm batch details and shipping arrangements before dispatch, so you know exactly what you are receiving.

How to Order Gilotrif (Afatinib)

Reach our team on WhatsApp at +86 15234153837 or by email at [email protected]. Let us know your preferred pack size, quantity, and destination country, and we will confirm availability, pricing, and delivery timelines.

FAQ

Are Gilotrif, Giotrif and Xovoltib the same drug? Yes. They are all afatinib tablets from Boehringer Ingelheim, marketed under different brand names in different regions. The active ingredient and manufacturing standards are identical.

What is the difference between the 30-tablet and 28-tablet packs? They reflect regional packaging conventions — 30 tablets is common in North America and 28 in Europe. Both contain 40 mg tablets and cover roughly one month of once-daily therapy.

Is afatinib a first-line treatment? Yes, for metastatic NSCLC with non-resistant EGFR mutations it is a recommended first-line option.

Can I switch between brand names? Any switch should be done under medical supervision, although the products are therapeutically equivalent as they share the same active ingredient and dose.